{"entity":{"id":"nct05174637","kind":"trial","name":"A Study of FDA018-ADC in Patients With Advanced Solid Tumors","aka":[],"tldr":"An early trial studying the safety and activity of experimental treatment. Its registry status does not establish patient benefit.","summary":"A Study of FDA018-ADC in Patients With Advanced Solid Tumors. ClinicalTrials.gov record last updated 2026-01-23: active not recruiting. Enrollment is planned at 78 participants. Primary completion is estimated at 2029-12. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications.","status":"active","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT05174637","url":"https://clinicaltrials.gov/study/NCT05174637"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["trop2"],"drugs":["fda018-adc"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["ClinicalTrials.gov record last updated 2026-01-23: active not recruiting. Enrollment is planned at 78 participants. Primary completion is estimated at 2029-12. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications."],"nct":"NCT05174637","phase":"1","setting":"A Study of FDA018-ADC in Patients With Advanced Solid Tumors","sponsor":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.","started":"2021-10-22","startedType":"actual","enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05174637/","neighbours":{"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"drug":[{"id":"fda018-adc","kind":"drug","name":"FDA018-ADC","route":"/drugs/fda018-adc/"}]}}